Questionnaire Study for Gynecological Cancer Survivors

NCT ID: NCT00391664

Last Updated: 2008-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-02-28

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the quality of life of long-term gynecologic cancer survivors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since the early 1970s, death rates for the major gynecological tumors have significantly declined, with a reduction of 42% for endometrial, 49% for cervix, 27% for vagina and vulva, and 11% for ovarian cancer. Thus, of the approximately 82,000 new gynecologic cases each year, more women will be living and, necessarily be forced to cope with psychological or behavioral morbidity. Psychosocial data on cancer patients portray significant fear and anxiety with diagnosis and treatments and the potential for high levels of psychological and sexual morbidity. While many studies have been done investigating sexual outcomes, little data is available on basic domains of quality of life, i.e. emotional or social adjustment, occupational outcomes, or aspects of physical health that might influence quality of life for gynecologic cancer survivors. There is a need for basic descriptive research in these areas, particularly in investigations that include representative samples from differing socioeconomic and racial/ethnic groups.

The goal of the proposed study is to evaluate quality of life in long-term gynecologic cancer survivors. The specific aims are to:

1. Describe quality of life (both mental health and physical functioning components), stress, and sexual functioning among survivors of gynecologic malignancies and
2. Describe differences between disease site groups (i.e. cervical, endometrial, ovarian, and vulva).

It has been shown with other cancer groups that improvements in mood and coping can be achieved with brief, cost effective interventions (e.g. ten therapy hours with delivery in a group format). These are multi-modal interventions with stress reduction, disease/treatment information, cognitive behavioral coping strategies, and social support. There is suggestive evidence that disease specific interventions, such as including sexual therapies for gynecologic patients, can result in improvements as well. Research focus on these issues is aided by the availability of reliable and valid strategies to assess both quality of life (SF-36; FACT) and sexuality. Before clinical trials are undertaken, research must provide a comprehensive assessment of quality of life for gynecologic cancer survivors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Vulvar Neoplasms Vaginal Neoplasms Genital Neoplasms, Female

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Endometrial cancer Ovarian Cancer Cervical Cancer Genital Cancer Vulvar Cancer Vaginal Cancer Other Gynecological Cancers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Psychosocial

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female participants diagnosed with gynecologic cancer
* Participants between the ages of 20 and 75 years old, inclusive
* Participants previously treated for all stages (I-IV) of the following cancers: cervix; endometrium; ovary; vulva; vagina; and other genital cancers
* Participants receiving treatment for their primary cancer in the past 2-10 years

Exclusion Criteria

* Male participants
* Participants with major psychoses (e.g. organic brain syndrome; schizophrenia; bipolar disorder; or mental retardation).
* Participants with significant hearing deficit
* Participants with prior non-gynecologic cancer diagnosis
* Participants who refused all forms of cancer treatment, whether standard of care or experimental.
* Participants with deficient ability to read/speak English
* Participants residing \>90 miles from the research site
* Participants diagnosed with dementia
* Participants diagnosed with pregnancy
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Walter Reed Army Medical Center

FED

Sponsor Role collaborator

Ohio State University

OTHER

Sponsor Role collaborator

U.S. Army Medical Research and Development Command

FED

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barbara L Andersen, PhD

Role: STUDY_DIRECTOR

Ohio State University

LTC G. Larry Maxwell, MD

Role: PRINCIPAL_INVESTIGATOR

Walter Reed Army Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Walter Reed Army Medical Center

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Ohio State University

Columbus, Ohio, United States

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laura Petersen

Role: CONTACT

Phone: (614) 292-6874

Email: [email protected]

Carolyn Hagopian

Role: CONTACT

Phone: (614) 292-3541

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Karen Livornese, BSN, RN

Role: primary

Cynthia A Perry, CIP

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

05-44025

Identifier Type: -

Identifier Source: org_study_id